Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Elicio Therapeutics (ELTX) EBITDA (2020 - 2026)

Elicio Therapeutics filings provide 4 years of EBITDA readings, the most recent being -$9.1 million for Q4 2023.

  • On a quarterly basis, EBITDA fell 37.14% to -$9.1 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$35.4 million, a 0.26% change, with the full-year FY2025 number at -$39.5 million, up 23.81% from a year prior.
  • EBITDA hit -$9.1 million in Q4 2023 for Elicio Therapeutics, up from -$10.7 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $14.9 million in Q4 2021 to a low of -$36.6 million in Q1 2021.
  • Median EBITDA over the past 4 years was -$11.9 million (2020), compared with a mean of -$12.9 million.
  • The widest YoY moves for EBITDA: up 150.99% in 2021, down 180.28% in 2021.
  • Elicio Therapeutics' EBITDA stood at -$29.1 million in 2020, then skyrocketed by 150.99% to $14.9 million in 2021, then crashed by 144.76% to -$6.7 million in 2022, then tumbled by 37.14% to -$9.1 million in 2023.
  • The last three reported values for EBITDA were -$9.1 million (Q4 2023), -$10.7 million (Q3 2023), and -$7.6 million (Q2 2023) per Business Quant data.